

Larisa V Gubareva

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4631884/publications.pdf>

Version: 2024-02-01

89
papers

11,986
citations

47006

47
h-index

46799

89
g-index

89
all docs

89
docs citations

89
times ranked

8864
citing authors

#	ARTICLE	IF	CITATIONS
1	Antivirals Targeting the Neuraminidase. Cold Spring Harbor Perspectives in Medicine, 2022, 12, a038455.	6.2	30
2	Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018â€“2020. Antiviral Research, 2022, 200, 105281.	4.1	44
3	Susceptibility of widely diverse influenza A viruses to PB2 polymerase inhibitor pimodivir. Antiviral Research, 2021, 188, 105035.	4.1	15
4	Influenza polymerase inhibitor resistance: Assessment of the current state of the art - A report of the isriv Antiviral group. Antiviral Research, 2021, 194, 105158.	4.1	24
5	Baloxavir and Treatment-Emergent Resistance: Public Health Insights and Next Steps. Journal of Infectious Diseases, 2020, 221, 337-339.	4.0	24
6	Detection of baloxavir resistant influenza A viruses using next generation sequencing and pyrosequencing methods. Antiviral Research, 2020, 182, 104906.	4.1	13
7	Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017â€“2018. Antiviral Research, 2020, 175, 104718.	4.1	91
8	Detection of oseltamivirâ€“resistant zoonotic and animal influenza A viruses using the rapid influenza antiviral resistance test. Influenza and Other Respiratory Viruses, 2019, 13, 522-527.	3.4	2
9	Replicative Fitness of Seasonal Influenza A Viruses With Decreased Susceptibility to Baloxavir. Journal of Infectious Diseases, 2019, 221, 367-371.	4.0	27
10	Susceptibility of Influenza A, B, C, and D Viruses to Baloxavir1. Emerging Infectious Diseases, 2019, 25, 1969-1972.	4.3	53
11	Insights into the antigenic advancement of influenza A(H3N2) viruses, 2011â€“2018. Scientific Reports, 2019, 9, 2676.	3.3	48
12	Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016/17 and 2017/18 seasons. Eurosurveillance, 2019, 24, .	7.0	86
13	Susceptibility of Brazilian influenza A(H1N1)pdm09 viruses to neuraminidase inhibitors in the 2014â€“2016 seasons: Identification of strains bearing mutations associated with reduced inhibition profile. Antiviral Research, 2018, 154, 35-43.	4.1	8
14	Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016â€“2017. Antiviral Research, 2018, 157, 38-46.	4.1	100
15	Mapping of the US Domestic Influenza Virologic Surveillance Landscape. Emerging Infectious Diseases, 2018, 24, 1300-1306.	4.3	21
16	Drug Susceptibility Evaluation of an Influenza A(H7N9) Virus by Analyzing Recombinant Neuraminidase Proteins. Journal of Infectious Diseases, 2017, 216, S566-S574.	4.0	33
17	The Household Influenza Vaccine Effectiveness Study: Lack of Antibody Response and Protection Following Receipt of 2014â€“2015 Influenza Vaccine. Clinical Infectious Diseases, 2017, 65, 1644-1651.	5.8	36
18	Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015â€“2016. Antiviral Research, 2017, 146, 12-20.	4.1	87

#	ARTICLE	IF	CITATIONS
19	A Pyrosequencing-Based Approach to High-Throughput Identification of Influenza A(H3N2) Virus Clades Harboring Antigenic Drift Variants. <i>Journal of Clinical Microbiology</i> , 2017, 55, 145-154.	3.9	6
20	Antiviral Drug-Resistant Influenza B Viruses Carrying H134N Substitution in Neuraminidase, Laos, February 2016. <i>Emerging Infectious Diseases</i> , 2017, 23, 686-690.	4.3	11
21	Update: Influenza Activity – United States and Worldwide, May 21–September 23, 2017. <i>Morbidity and Mortality Weekly Report</i> , 2017, 66, 1043-1051.	15.1	34
22	Monitoring influenza virus susceptibility to oseltamivir using a new rapid assay, iART. <i>Eurosurveillance</i> , 2017, 22, .	7.0	7
23	Enhanced Genetic Characterization of Influenza A(H3N2) Viruses and Vaccine Effectiveness by Genetic Group, 2014–2015. <i>Journal of Infectious Diseases</i> , 2016, 214, 1010-1019.	4.0	101
24	A randomized, double-blind, placebo-controlled trial evaluating the safety of early oseltamivir treatment among children 0–9 years of age hospitalized with influenza in El Salvador and Panama. <i>Antiviral Research</i> , 2016, 133, 85-94.	4.1	23
25	Human Monoclonal Antibody 81.39a Effectively Neutralizes Emerging Influenza A Viruses of Group 1 and 2 Hemagglutinins. <i>Journal of Virology</i> , 2016, 90, 10446-10458.	3.4	16
26	Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014–2015. <i>Antiviral Research</i> , 2016, 132, 178-185.	4.1	155
27	Structural and Functional Analysis of Surface Proteins from an A(H3N8) Influenza Virus Isolated from New England Harbor Seals. <i>Journal of Virology</i> , 2015, 89, 2801-2812.	3.4	13
28	Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013–2014. <i>Antiviral Research</i> , 2015, 117, 27-38.	4.1	132
29	Neuraminidase Mutations Conferring Resistance to Oseltamivir in Influenza A(H7N9) Viruses. <i>Journal of Virology</i> , 2015, 89, 5419-5426.	3.4	59
30	Emergence of Multidrug-Resistant Influenza A(H1N1)pdm09 Virus Variants in an Immunocompromised Child Treated With Oseltamivir and Zanamivir. <i>Journal of Infectious Diseases</i> , 2015, 212, 1209-1213.	4.0	56
31	Application of a Seven-Target Pyrosequencing Assay To Improve the Detection of Neuraminidase Inhibitor-Resistant Influenza A(H3N2) Viruses. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2374-2379.	3.2	9
32	Oseltamivir-Resistant Influenza A(H1N1)pdm09 Viruses, United States, 2013–14. <i>Emerging Infectious Diseases</i> , 2015, 21, 136-141.	4.3	45
33	Characterization of Drug-Resistant Influenza A(H7N9) Variants Isolated From an Oseltamivir-Treated Patient in Taiwan. <i>Journal of Infectious Diseases</i> , 2015, 211, 249-257.	4.0	73
34	Oseltamivir-Resistant Influenza A(H1N1)pdm09 Viruses, United States, 2013–14. <i>Emerging Infectious Diseases</i> , 2015, 21, 136-141.	4.3	20
35	Influenza activity - United States, 2014-15 season and composition of the 2015-16 influenza vaccine. <i>Morbidity and Mortality Weekly Report</i> , 2015, 64, 583-90.	15.1	105
36	An Investigational Antiviral Drug, DAS181, Effectively Inhibits Replication of Zoonotic Influenza A Virus Subtype H7N9 and Protects Mice From Lethality. <i>Journal of Infectious Diseases</i> , 2014, 210, 435-440.	4.0	48

#	ARTICLE	IF	CITATIONS
37	Drug susceptibility surveillance of influenza viruses circulating in the United States in 2011–2012: application of the WHO antiviral working group criteria. <i>Influenza and Other Respiratory Viruses</i> , 2014, 8, 258-265.	3.4	33
38	Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 109-118.	9.1	114
39	The effect of the MDCK cell selected neuraminidase D151G mutation on the drug susceptibility assessment of influenza A(H3N2) viruses. <i>Antiviral Research</i> , 2014, 101, 93-96.	4.1	29
40	Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012–2013. <i>Antiviral Research</i> , 2014, 110, 31-41.	4.1	85
41	Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season. <i>Influenza and Other Respiratory Viruses</i> , 2013, 7, 645-658.	3.4	51
42	Cell Culture-Selected Substitutions in Influenza A(H3N2) Neuraminidase Affect Drug Susceptibility Assessment. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 6141-6146.	3.2	41
43	Assays for monitoring susceptibility of influenza viruses to neuraminidase inhibitors. <i>Influenza and Other Respiratory Viruses</i> , 2013, 7, 44-49.	3.4	43
44	A Cluster of Patients Infected With I221V Influenza B Virus Variants With Reduced Oseltamivir Susceptibility—North Carolina and South Carolina, 2010–2011. <i>Journal of Infectious Diseases</i> , 2013, 207, 966-973.	4.0	27
45	Antiviral Susceptibility of Highly Pathogenic Avian Influenza A(H5N1) Viruses Isolated from Poultry, Vietnam, 2009–2011. <i>Emerging Infectious Diseases</i> , 2013, 19, 1963-1971.	4.3	30
46	Bioluminescence-Based Neuraminidase Inhibition Assay for Monitoring Influenza Virus Drug Susceptibility in Clinical Specimens. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 5209-5215.	3.2	12
47	Outbreak of Variant Influenza A(H3N2) Virus in the United States. <i>Clinical Infectious Diseases</i> , 2013, 57, 1703-1712.	5.8	144
48	R292K Substitution and Drug Susceptibility of Influenza A(H7N9) Viruses. <i>Emerging Infectious Diseases</i> , 2013, 19, 1521-1524.	4.3	63
49	Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods. <i>Antiviral Therapy</i> , 2012, 17, 159-173.	1.0	161
50	Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 240-248.	9.1	186
51	Oseltamivir-Resistant Pandemic (H1N1) 2009 Virus Infections, United States, 2010–11. <i>Emerging Infectious Diseases</i> , 2012, 18, 308-311.	4.3	89
52	Human Infections with Novel Reassortant Influenza A(H3N2)v Viruses, United States, 2011. <i>Emerging Infectious Diseases</i> , 2012, 18, 834-837.	4.3	117
53	The Fluorescence Neuraminidase Inhibition Assay: A Functional Method for Detection of Influenza Virus Resistance to the Neuraminidase Inhibitors. <i>Methods in Molecular Biology</i> , 2012, 865, 115-125.	0.9	33
54	The Chemiluminescent Neuraminidase Inhibition Assay: A Functional Method for Detection of Influenza Virus Resistance to the Neuraminidase Inhibitors. <i>Methods in Molecular Biology</i> , 2012, 865, 95-113.	0.9	13

#	ARTICLE	IF	CITATIONS
55	Analysis of influenza viruses from patients clinically suspected of infection with an oseltamivir resistant virus during the 2009 pandemic in the United States. <i>Antiviral Research</i> , 2012, 93, 381-386.	4.1	43
56	RT-PCR/electrospray ionization mass spectrometry approach in detection and characterization of influenza viruses. <i>Expert Review of Molecular Diagnostics</i> , 2011, 11, 41-52.	3.1	37
57	Influenza B Viruses with Mutation in the Neuraminidase Active Site, North Carolina, USA, 2010-11. <i>Emerging Infectious Diseases</i> , 2011, 17, 2043-6.	4.3	31
58	Cluster of Oseltamivir-Resistant 2009 Pandemic Influenza A (H1N1) Virus Infections on a Hospital Ward among Immunocompromised Patients—North Carolina, 2009. <i>Journal of Infectious Diseases</i> , 2011, 203, 838-846.	4.0	83
59	Detection of Hemagglutinin Variants of the Pandemic Influenza A (H1N1) 2009 Virus by Pyrosequencing. <i>Journal of Clinical Microbiology</i> , 2011, 49, 1307-1312.	3.9	30
60	Characteristics of Patients with Oseltamivir-Resistant Pandemic (H1N1) 2009, United States. <i>Emerging Infectious Diseases</i> , 2011, 17, 255-257.	4.3	66
61	Dual Resistance to Adamantanes and Oseltamivir Among Seasonal Influenza A(H1N1) Viruses: 2008-2010. <i>Journal of Infectious Diseases</i> , 2011, 203, 13-17.	4.0	119
62	A Human Monoclonal Antibody with Neutralizing Activity against Highly Divergent Influenza Subtypes. <i>PLoS ONE</i> , 2011, 6, e28001.	2.5	49
63	Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro. <i>Antiviral Therapy</i> , 2010, 15, 1151-1159.	1.0	86
64	Detection of antiviral resistance and genetic lineage markers in influenza B virus neuraminidase using pyrosequencing. <i>Antiviral Research</i> , 2010, 85, 354-360.	4.1	37
65	Host cell selection of influenza neuraminidase variants: Implications for drug resistance monitoring in A(H1N1) viruses. <i>Antiviral Research</i> , 2010, 85, 381-388.	4.1	88
66	Detection of E119V and E119I Mutations in Influenza A (H3N2) Viruses Isolated from an Immunocompromised Patient: Challenges in Diagnosis of Oseltamivir Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 1834-1841.	3.2	74
67	Detection of Molecular Markers of Drug Resistance in 2009 Pandemic Influenza A (H1N1) Viruses by Pyrosequencing. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 1102-1110.	3.2	116
68	Antiviral Treatment of Patients with Oseltamivir-Resistant and Oseltamivir-Susceptible Seasonal Influenza A (H1N1) Infection during the 2007-2008 Influenza Season in the United States. <i>Clinical Infectious Diseases</i> , 2010, 50, 621-622.	5.8	21
69	<i>In Vitro</i> Antiviral Activity of Favipiravir (T-705) against Drug-Resistant Influenza and 2009 A(H1N1) Viruses. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 2517-2524.	3.2	134
70	Current Challenges in the Risk Assessment of Neuraminidase Inhibitor-Resistant Influenza Viruses. <i>Journal of Infectious Diseases</i> , 2010, 201, 656-658.	4.0	7
71	Assessment of Pandemic and Seasonal Influenza A (H1N1) Virus Susceptibility to Neuraminidase Inhibitors in Three Enzyme Activity Inhibition Assays. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 3671-3677.	3.2	81
72	Recovery of a Multidrug-Resistant Strain of Pandemic Influenza A 2009 (H1N1) Virus Carrying a Dual H275Y/I223R Mutation from a Child after Prolonged Treatment with Oseltamivir. <i>Clinical Infectious Diseases</i> , 2010, 51, 983-984.	5.8	104

#	ARTICLE	IF	CITATIONS
73	Neuraminidase Inhibitor Susceptibility Testing in Human Influenza Viruses: A Laboratory Surveillance Perspective. <i>Viruses</i> , 2010, 2, 2269-2289.	3.3	72
74	Novel Pandemic Influenza A(H1N1) Viruses Are Potently Inhibited by DAS181, a Sialidase Fusion Protein. <i>PLoS ONE</i> , 2009, 4, e7788.	2.5	91
75	Infections With Oseltamivir-Resistant Influenza A(H1N1) Virus in the United States. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 1034.	7.4	465
76	Pyrosequencing as a tool to detect molecular markers of resistance to neuraminidase inhibitors in seasonal influenza A viruses. <i>Antiviral Research</i> , 2009, 81, 16-24.	4.1	85
77	Genomic events underlying the changes in adamantane resistance among influenza A(H3N2) viruses during 2006-2008. <i>Influenza and Other Respiratory Viruses</i> , 2009, 3, 297-314.	3.4	21
78	Antigenic and Genetic Characteristics of Swine-Origin 2009 A(H1N1) Influenza Viruses Circulating in Humans. <i>Science</i> , 2009, 325, 197-201.	12.6	2,127
79	Influenza genome analysis using pyrosequencing method: current applications for a moving target. <i>Expert Review of Molecular Diagnostics</i> , 2009, 9, 493-509.	3.1	46
80	Emergence of a Novel Swine-Origin Influenza A (H1N1) Virus in Humans. <i>New England Journal of Medicine</i> , 2009, 360, 2605-2615.	27.0	2,732
81	Surveillance for Neuraminidase Inhibitor Resistance among Human Influenza A and B Viruses Circulating Worldwide from 2004 to 2008. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 3284-3292.	3.2	441
82	Surveillance of Resistance to Adamantanes among Influenza A(H3N2) and A(H1N1) Viruses Isolated Worldwide. <i>Journal of Infectious Diseases</i> , 2007, 196, 249-257.	4.0	501
83	Comparative Activities of Oseltamivir and A-22278 in Immunocompetent and Immunocompromised Murine Models of Influenza Virus Infection. <i>Journal of Infectious Diseases</i> , 2006, 193, 765-772.	4.0	54
84	Recovery of Drug-Resistant Influenza Virus from Immunocompromised Patients: A Case Series. <i>Journal of Infectious Diseases</i> , 2006, 193, 760-764.	4.0	253
85	Sialidase Fusion Protein as a Novel Broad-Spectrum Inhibitor of Influenza Virus Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 1470-1479.	3.2	211
86	Susceptibilities of Antiviral-Resistant Influenza Viruses to Novel Neuraminidase Inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 4515-4520.	3.2	197
87	Efficacy and Tolerability of the Oral Neuraminidase Inhibitor Peramivir in Experimental Human Influenza: Randomized, Controlled Trials for Prophylaxis and Treatment. <i>Antiviral Therapy</i> , 2005, 10, 901-910.	1.0	99
88	Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay. <i>Antiviral Research</i> , 2002, 53, 47-61.	4.1	139
89	Symptom pathogenesis during acute influenza: Interleukin-6 and Other cytokine responses. <i>Journal of Medical Virology</i> , 2001, 64, 262-268.	5.0	320